| Disease state: | |
|---|---|
| Non-metastatic | Disease is either localized (confined to the prostate), locally advanced (confined to the pelvic region), or recurrent with no evidence of distant metastasis on scans |
| Metastatic | metastatic disease is seen on scans |
| Disease stage: | |
|---|---|
| Newly diagnosed | Trials for patients who have recently received a diagnosis of localized or metastatic prostate cancer. *Includes trials for patients who have not yet been treated, or who have been treated recently for localized disease with no evidence of recurrence |
| Recurrence | Trials for patients who have previously undergone treatment for localized prostate cancer (prostatectomy or radiation therapy) and are experiencing a PSA recurrence *Hormone therapy is the primary treatment for metastatic prostate cancer; as such, patients who recur after hormone therapy for metastatic disease are classified as “castration resistant”. |
| Castration resistant | Trials for patients who have disease progression after hormone therapy |
| Non-adenocarcinoma of the prostate | Trials specifically for patients with “neuroendocrine prostate cancer” NEPC. |
| Survivor | Trials for prostate cancer survivors who have previously been treated, are not currently undergoing treatment, and have no evidence of disease. *Trials in this category mainly test quality of life improvements. |
| Active surveillance | Trials for patients with localized prostate cancer who are currently undergoing or are candidates for active surveillance. |
*Because of the way trials are tagged (some trials apply to patients in many categories), some trials that that may not apply to the criteria selected can appear in the tables.